1. A5.28 Semaphorin3A is a Potent B Cell Regulatory Molecule in SLE. (25th February 2013) Authors: Vadasz, Zahava; Toubi, Elias Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 1(2013) Page Start: A40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A8.39 Regulatory role for CD72 Expression on B cells in SLE. (31st January 2014) Authors: Vadasz, Zahava; Toubi, Elias Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 1(2014) Page Start: A92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0189 DECREASED URINE SEMAPHORIN 3A SECRETION PREDICTS THE EXTENT OF RENAL DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. (June 2019) Authors: Rimar, Doron; Lidar, Merav; Eiza, Nasrin; Toubi, Elias; Silawy, Amal; Slobodin, Gleb; Rosner, Itzhak; Rosenbaum, Michael; Awisat, Abid; Boulman, Nina; Kaly, Lisa; Ginsberg, Shira; Jiries, Nizar; Vadasz, Zahava Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 1551 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Brief Report: Lysyl Oxidase Is a Potential Biomarker of Fibrosis in Systemic Sclerosis. Issue 3 (March 2014) Authors: Rimar, Doron; Rosner, Itzhak; Nov, Yuval; Slobodin, Gleb; Rozenbaum, Michael; Halasz, Katy; Haj, Tharwat; Jiries, Nizar; Kaly, Lisa; Boulman, Nina; Daood, Rula; Vadasz, Zahava Journal: Arthritis & rheumatology Issue: Volume 66:Issue 3(2014) Page Start: 726 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. B‐regulatory cells in autoimmunity and immune mediated inflammation. Issue 13 (22nd May 2013) Authors: Vadasz, Zahava; Haj, Tharwat; Kessel, Aharon; Toubi, Elias Journal: FEBS letters Issue: Volume 587:Issue 13(2013) Page Start: 2074 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. CD72-semaphorin3A axis: A new regulatory pathway in systemic lupus erythematosus. Issue 134 (January 2023) Authors: Eiza, Nasren; Sabag, Adi D.; Kessler, Ofra; Neufeld, Gera; Vadasz, Zahava Journal: Journal of autoimmunity Issue: Issue 134(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Predictive features associated with chronic spontaneous urticaria recurrence. Issue 11 (14th September 2021) Authors: Toubi, Elias; Vadasz, Zahava Journal: Journal of dermatology Issue: Volume 48:Issue 11(2021) Page Start: 1786 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure?. (10th March 2018) Authors: Willner, Nadav; Goldberg, Yair; Schiff, Elad; Vadasz, Zahava Journal: ESC heart failure Issue: Volume 5:Number 4(2018) Page Start: 603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Semaphorin-3A inhibits multiple myeloma progression in a mouse model. (9th August 2018) Authors: Lavi, Noa; Kessler, Ofra; Ziv, Keren; Nir-Zvi, Inbal; Mumblat, Yelena; Eiza, Nasrene; Paran, Yael; Brenner, Benjamin; Vadasz, Zahava; Neufeld, Gera Journal: Carcinogenesis Issue: Volume 39:Number 10(2018) Page Start: 1283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Semaphorin3A is a promising therapeutic tool for bronchial asthma. Issue 2 (20th October 2019) Authors: Toubi, Elias; Vadasz, Zahava Journal: Allergy Issue: Volume 75:Issue 2(2020) Page Start: 481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗